Stop STALLING Act aims to prevent sham petitions that delay generic drug approvals.
The Stop STALLING Act empowers the Federal Trade Commission to address sham petitions submitted to delay generic drug approvals. It defines "sham" petitions as baseless attempts to interfere with competitors. The Act allows the FTC to take civil action against those submitting such petitions, imposing penalties and other relief. It also ensures that antitrust laws remain applicable to unfair competition methods.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.